Table 1.
GRADE certainty-of-evidence table for all recommendations
| TOPIC | GRADE CERTAINTY OF EVIDENCE |
|---|---|
| Screening and testing | |
| • Lipid testing | High |
| • CAC in cardiovascular risk assessment | Moderate |
| • Lp(a) and apoB in cardiovascular risk assessment | High |
| Interventions | |
| • Physical activity | Low |
| • Mediterranean diet | Moderate |
| • Statins for primary prevention (CVD risk ≥20%) | High |
| • Statins for primary prevention (CVD risk 10%-19%) | High |
| • Non-statins for primary prevention | Moderate |
| • Statins for secondary prevention | High |
| • Non-statins for secondary prevention | High |
| Considerations in patients older than 75 y | |
| • Lipid testing for primary prevention | Moderate |
| • Statins for primary prevention | Moderate |
| • Statin initiation for secondary prevention | High |
| • Statin continuation for secondary prevention | Moderate |
| • Statins and cognition | Low |
| Statin intolerance | |
| • Statin intolerance (rechallenging) | High |
| • Statin intolerance in primary prevention (other drugs) | Low |
| • Statin intolerance in secondary prevention (other drugs) | Low |
| Follow-up | |
| • Lipid targets and repeat testing after lipid-lowering therapy | Not applicable |
| • Baseline CK and ALT testing before lipid-lowering therapy | Not applicable |
ALT—alanine aminotransferase; apoB—apolipoprotein B; CAC—coronary artery calcium; CK—creatine kinase; CVD—cardiovascular disease; GRADE—Grading of Recommendations Assessment, Development and Evaluation; Lp(a)—lipoprotein a.